{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:39:14Z","timestamp":1774384754975,"version":"3.50.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/jcp.0b013e3182905d42","type":"journal-article","created":{"date-parts":[[2013,6,15]],"date-time":"2013-06-15T11:05:57Z","timestamp":1371294357000},"page":"561-564","source":"Crossref","is-referenced-by-count":11,"title":["Interaction of Valproic Acid and Amitriptyline"],"prefix":"10.1097","volume":"33","author":[{"given":"Stefan","family":"Unterecker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelie","family":"Hohage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Deckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Pfuhlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1049909111412539","article-title":"A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study.","volume":"29","author":"Mishra","year":"2012","journal-title":"Am J Hosp Palliat Care"},{"key":"R2-20-20210128","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1755-5949.2010.00170.x","article-title":"The use of antidepressants for headache prophylaxis.","volume":"17","author":"Smitherman","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"R3-20-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00002512-200320020-00005","article-title":"Drug treatment of epilepsy in elderly people: focus on valproic acid.","volume":"20","author":"Stephen","year":"2003","journal-title":"Drugs Aging"},{"key":"R4-20-20210128","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2147\/NDT.S24966","article-title":"A comprehensive review of the literature on epilepsy in selected countries in emerging markets.","volume":"7","author":"Angalakuditi","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R5-20-20210128","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1528-1167.2011.03243.x","article-title":"Rational polytherapy in the treatment of acute seizures and status epilepticus.","volume":"52","author":"Wasterlain","year":"2011","journal-title":"Epilepsia"},{"key":"R6-20-20210128","first-page":"51","article-title":"The use of anticonvulsants to augment antidepressant medication.","volume":"59","author":"Dietrich","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R7-20-20210128","first-page":"CD005653","article-title":"Pharmacological interventions for borderline personality disorder.","volume":"16","author":"Stoffers","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R8-20-20210128","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1756285611401647","article-title":"Management of vestibular migraine.","volume":"4","author":"Bisdorff","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"R9-20-20210128","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/mus.22092","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathyreport of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine Rehabilitation.","volume":"43","author":"Bril","year":"2011","journal-title":"Muscle Nerve"},{"key":"R10-20-20210128","first-page":"S153","article-title":"Which therapy for which patient Neurol Sci.","volume":"27","author":"Pierangeli","year":"2006","journal-title":""},{"key":"R11-20-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11940-010-0104-7","article-title":"Update on chronic daily headache.","volume":"13","author":"Couch","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"R12-20-20210128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000202824","article-title":"Antidepressant-induced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs.","volume":"59","author":"Koszewska","year":"2009","journal-title":"Neuropsychobiology"},{"key":"R13-20-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1034\/j.1399-5618.2003.00031.x","article-title":"Valproate.","volume":"5","author":"Bowden","year":"2003","journal-title":"Bipolar Disord"},{"key":"R14-20-20210128","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2165\/00003495-200868110-00003","article-title":"Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs.","volume":"68","author":"Miller","year":"2008","journal-title":"Drugs"},{"key":"R15-20-20210128","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1468-1331.1996.tb00435.x","article-title":"Recurrence of absence seizures induced by a low dose of amitriptyline: a case report.","volume":"3","author":"Avoni","year":"1996","journal-title":"Eur J Neurol"},{"key":"R16-20-20210128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R17-20-20210128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs.","volume":"61","author":"Perucca","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R18-20-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"R19-20-20210128","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1528-1157.2002.043s2037.x","article-title":"Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.","volume":"43","author":"Spina","year":"2002","journal-title":"Epilepsia"},{"key":"R20-20-20210128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0009-9236(96)90166-6","article-title":"Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics.","volume":"60","author":"Wong","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"R21-20-20210128","first-page":"386","article-title":"Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients.","volume":"10","author":"Vandel","year":"1988","journal-title":"Ther Drug Monit"},{"key":"R22-20-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00004714-199406000-00009","article-title":"Valproatenortriptyline interaction.","volume":"14","author":"Fu","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"R23-20-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2125.1999.00973.x","article-title":"Pharmacokinetic and pharmacodynamic characterizations of OROS and immediate-release amitriptyline.","volume":"48","author":"Gupta","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R24-20-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/026988110101500305","article-title":"Pharmacokinetics of valproic acid in patients with bipolar disorder.","volume":"15","author":"Vasudev","year":"2001","journal-title":"J Psychopharmacol"},{"key":"R25-20-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-3-211-73574-9_35","article-title":"Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice.","volume":"72","author":"Pfuhlmann","year":"2007","journal-title":"J Neural Transm Suppl"},{"key":"R26-20-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1445-5994.2006.01286.x","article-title":"Drug-induced Brugada syndrome with ST-T wave alternans and long QT.","volume":"37","author":"Roberts-Thomson","year":"2007","journal-title":"Intern Med J"},{"key":"R27-20-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00007691-199702000-00012","article-title":"Status epilepticus associated with the combination of valproic acid and clomipramine.","volume":"19","author":"DeToledo","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R28-20-20210128","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00004714-200008000-00019","article-title":"Increase of serum clomipramine concentrations caused by valproate.","volume":"20","author":"Fehr","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R29-20-20210128","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00414-007-0184-4","article-title":"Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms.","volume":"122","author":"Thieme","year":"2008","journal-title":"Int J Legal Med"},{"key":"R30-20-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1046\/j.1365-2125.1996.35717.x","article-title":"Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation.","volume":"41","author":"Schmider","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"R31-20-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2125.1997.05382.x","article-title":"Cytochromes P450 mediating the N-demethylation of amitriptyline.","volume":"43","author":"Ghahramani","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R32-20-20210128","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1177\/00912700122012634","article-title":"Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies.","volume":"41","author":"Venkatakrishnan","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R33-20-20210128","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0022-3565(24)29543-4","article-title":"Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate.","volume":"297","author":"Venkatakrishnan","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R34-20-20210128","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/j.1552-4604.1998.tb04399.x","article-title":"Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4.","volume":"38","author":"Venkatakrishnan","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"R35-20-20210128","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1081\/DMR-200033482","article-title":"The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man.","volume":"36","author":"Breyer-Pfaff","year":"2004","journal-title":"Drug Metab Rev"},{"key":"R36-20-20210128","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).","volume":"52","author":"Wen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R37-20-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database.","volume":"31","author":"Reis","year":"2009","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3182905d42","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T12:15:15Z","timestamp":1746015315000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201308000-00020"}},"subtitle":["Analysis of Therapeutic Drug Monitoring Data Under Naturalistic Conditions"],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182905d42","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}